Topics
Glioblastoma | Treatment | Targeted therapy | Depatuxizumab mafodotin
Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > Depatuxizumab mafodotin
Moghib K, Hassan MA, Eljadid GY, Salomon I, Algazar MA, Abu Arafeh
MW, Baklola M, Hafez W, Ibrahim IA.
Safety
and efficacy of depatuxizumab mafodotin monotherapy or in
combination with temozolomide in patients with/without
EGFR-amplified recurrent glioblastoma: a systematic review.
Ann
Med Surg (Lond). 2025 Sep 17;87(11):7478-7494. doi:
10.1097/MS9.0000000000003869. PMID:
41180763. Review. ˍ
Lassman AB, Pugh SL, Wang TJC, Aldape K, Gan HK, Preusser M,
Vogelbaum MA, Sulman EP, Won M, Zhang P, Moazami G, Macsai MS,
Gilbert MR, Bain EE, Blot V, Ansell PJ, Samanta S, Kundu MG,
Armstrong TS, Wefel JS, Seidel C, de Vos FY, Hsu S, Cardona AF,
Lombardi G, Bentsion D, Peterson RA, Gedye C, Bourg V, Wick A,
Curran WJ, Mehta MP.
Depatuxizumab
mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase
III randomized clinical trial.
Neuro
Oncol. 2023 Feb 14;25(2):339-350. doi:
10.1093/neuonc/noac173. (Erratum in:
Neuro
Oncol. 2026 Feb 26:noag031. doi:
10.1093/neuonc/noag031). PMID:
35849035. Interventional study. ˍ